Latest SEC filings for Beam Therapeutics Inc. (BEAM) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
CAROLE HO filed a Form 144 with the SEC indicating intent to sell BEAM (Beam Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.
Evans John M., listed as Director, CEO at Beam Therapeutics Inc., reported an open-market sale of 30,078 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Simon Amy, listed as Chief Medical Officer at Beam Therapeutics Inc., reported an open-market sale of 6,700 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Cavanagh Bethany J, listed as SVP, Finance and Treasurer at Beam Therapeutics Inc., reported an open-market sale of 3,242 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bellon Christine, listed as Chief Legal Officer at Beam Therapeutics Inc., reported an open-market sale of 5,956 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Ciaramella Giuseppe, listed as President at Beam Therapeutics Inc., reported an open-market sale of 11,810 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bellon Christine (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Cavanagh Bethany J (SVP, Finance and Treasurer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Simon Amy (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Emany Sravan Kumar (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Ciaramella Giuseppe (President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Evans John M., listed as Director, CEO at Beam Therapeutics Inc., reported an open-market sale of 50,000 BEAM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
CHRISTINE BELLON filed a Form 144 with the SEC indicating intent to sell BEAM (Beam Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
GIUSEPPE CIARAMELLA filed a Form 144 with the SEC indicating intent to sell BEAM (Beam Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
AMY SIMON filed a Form 144 with the SEC indicating intent to sell BEAM (Beam Therapeutics Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.